Mintz Levin Health Care Qui Tam Update: Recent Developments & Unsealed Cases - September 2015

by Mintz - Health Care Viewpoints

Trends & Analysis

Since our last Qui Tam Update, we have identified 39 health-related False Claims Act (“FCA”) qui tam cases that have been unsealed. Of those cases:

  • 19 were filed between 2009 and 2013 (with seven filed in each of 2012 and 2013)
  • 18 were filed in 2014
  • 2 were filed in 2015

These cases were filed in federal district court in 20 states scattered across the country, plus the District of Columbia. Notably, seven cases were filed in California (with five being filed in the Central District of California (Los Angeles)). Four cases were filed in New York (three of them in the Southern District (Manhattan)), and three cases were filed in New Jersey.

Within the 39 cases we reviewed:

  • The government elected to intervene in full in five cases.
  • The government partially intervened in one case.
  • The government declined to intervene in 21 cases.
  • The government’s decision on whether to intervene is still pending in two cases and cannot be determined from the docket in seven cases.
  • Relators voluntarily dismissed seven cases.
  • There have been settlements associated with five of the identified cases.
  • 21 of the cases alleged state and federal claims, one of which also asserted claims under the municipal false claims acts of Chicago and New York City.
  • Eight cases included claims for retaliation.

Subject matter of claims:

  • A number of cases involved claims that the defendants billed for products or services that were not actually provided, engaged in upcoding, or billed for services of non-physician providers under physicians’ names.
  • One case alleged the use of unqualified and unlicensed personnel to serve as x-ray technicians, allegedly in knowing violation of the conditions applicable to payment for claims submitted by x-ray technicians.
  • In a few cases, the government declined to intervene and the relator sought to dismiss the allegations voluntarily. In one case, the relator asked the court to maintain the seal, but the court unsealed the complaint anyway.
  • This month’s cases include yet another case brought by serial relator Fox, Rx, parent company of Fox Insurance, Inc., both of which were in the business of sponsoring Medicare Part D prescription drug plans. Now, both seem to be engaged primarily in bringing qui tam actions. (Previous Fox, Rx qui tam actions were discussed in the November 2013, October 2014 and March 2015 Updates). Fox allegedly conducted an internal audit of its claims and determined that AccessHealth, a pharmacy service provider, had purportedly dispensed hundreds of thousands of Schedule II controlled substances without prescriptions.
  • Another case, which the relator voluntarily dismissed with the government’s agreement, alleged false certifications of compliance with conditions for the receipt of payment from the Medicare Shared Savings Program through participation in an Accountable Care Organization.
  • The relator in one case was a limited liability company formed for the sole purpose of filing the qui tam action. The practice of forming legal entities solely for the purpose of bringing qui tam cases is a trend that we are seeing with increasing frequency, and it appears to us that they are created, at least in some instances, to conceal the relator’s identity.
  • The relators in many of the cases were former employees, although some relators came from defendants’ competitors or service providers.

Recently Unsealed Cases

United States of America ex rel. Mazurek v. Garden State Cardiovascular Specialists, P.C., No. 2:10-cv-04734 (D.N.J.)

Complaint Filed: September 14, 2010

Complaint Unsealed: June 1, 2015

Intervention Status: The federal government intervened as to Garden State Cardiovascular Specialists P.C. (“Garden State”) for purposes of settlement. The government declined to intervene as to defendant Medigain, Inc. (“Medigain”).

Claims: False claims to Medicare and Tricare in violation of the 1986 and 2009 versions of the FCA for false claims (31 U.S.C. § 3729(a)(1)(1986), 31 U.S.C. § 3729(a)(1)(A)(2009)); false statements (31 U.S.C. § 3729 (a)(2) (1986), 31 U.S.C. § 3729(a)(1)(B)(2009)); and conspiracy (31 U.S.C. § 3729 (a)(3)(1986), 31 U.S.C. § 3729(a)(1)(C)(2009)). The relator also asserted violations of the federal Anti-Kickback Statute (“AKS”) as the basis for an FCA violation. The relator sued under the New Jersey False Claims Act for false claims to Medicaid, as well. In addition, the relator brought a retaliation claim against Medigain, alleging that it terminated her after she raised concerns about certain Garden State billing practices.

Name of Relator: Cheryl Mazurek

Defendants’ Businesses: Garden State is a cardiology practice that owns and operates several facilities. Medigain provides services related to billing, reimbursement, and revenue cycle management.

Relator’s Relationship to Defendants: The relator was a Medigain employee.

Relator’s Counsel: Begelman & Orlow, P.C.

Summary of Case: Garden State allegedly contracted with Medigain to provide electronic billing services. Medigain submitted electronic claims for Garden State to Medicare, Medicaid, and Tricare, among other government health care programs. The relator worked for Medigain and asserted that she identified allegedly improper claims through a number of means, including an “office audit” of Garden State’s claims (some of which she attached to her complaint). The relator asserted that she informed Medigain of certain alleged billing improprieties. The complaint charged that Garden State’s claims were false in several different ways, including (1) using the NPI number of a physician who did not perform the service for which Garden State sought payment; (2) billing federal health care programs for medically unnecessary cardiology diagnostic tests and procedures, including stress tests, cardiac catheterizations, and external counterpulsation services; and (3) “upcoding” services to obtain higher reimbursement rates.

The complaint further alleged that Garden State asked Medigain to file false claims and that Medigain purportedly filed false claims in exchange for payment from Garden State.

Current Status: On May 28, 2015, Garden State and its principals, Jasjit Walia, M.D., and Preet Randhawa, M.D., settled the medical necessity case against them for $3.6 million. The relator received $648,000 of the settlement proceeds. The relator advised the court on June 25, 2015 that she would serve the complaint against Medigain and that she would proceed with that portion of the lawsuit on her own.

Reasons to Watch: This case is another reminder that relators are often billing and coding specialists who may work for third-party billing or auditing companies. Companies can mitigate the risk that employees will become qui tam relators by instituting processes and procedures that can be used to surface and act on issues identified by employees. Where a company uses a third-party vendor, the company might want to consider adopting contractual provisions obligating the vendor to implement similar controls so that compliance issues come to light in the course of the company-vendor relationship, and not through an OIG subpoena or the unsealing of a qui tam action.

In addition, the case exemplifies a trend that we are seeing with increasing frequency: relators are more willing than ever to press ahead with claims on their own, even if the government declines to intervene as to certain, or even all, claims. In this case, even though the government intervened in part, and settled a portion of the case, it appears that the relator will continue the litigation as to certain claims that the government declined to pursue itself.

United States of America ex rel. Morris v. Brevard Eye Center, Inc., No. 6:14-cv-01460 (M.D. Fl.)

Complaint Filed: September 5, 2014

Complaint Unsealed: Not clear from the docket.

Intervention Status: No reference to intervention or declination in the docket.

Claims: Submission of false claims in violation of the FCA (31 U.S.C. § 3729(a)(1)(A)); false statements (31 U.S.C. § 3729 (a)(1)(B)); and concealing and avoiding an obligation to pay money to the United States (31 U.S.C. § 3729(a)(1)(G)). The relator also alleged that the defendants had violated the Florida state statutes applicable to false claims and concealing or avoiding the obligation to pay money to the state. Finally, the relator included a retaliation claim against the defendants in the lawsuit.

Name of Relator: Carrie L. Morris, M.D.

Defendants’ Business: Brevard Eye Center, Inc. (“BEC”) is a medical eye care facility with seven locations in Brevard County, Florida. Brevard Surgery Center, Inc. (the “Surgery Center”) is an ambulatory surgery center affiliated with BEC. The relator also named several individuals as defendants, including the president of the Surgery Center, the CEO of BEC and the Surgery Center, the vice president and treasurer of both BEC and the Surgery Center, the president of BEC and the Surgery Center, and several individual optometrists either currently or formerly employed by BEC.

Relator’s Relationship to Defendant: The relator was a BEC employee.

Relator’s Counsel: Jill S. Schwartz & Associates, P.C.

Summary of Case: The relator asserted that the CEO of BEC orchestrated a number of schemes to defraud federal health care programs with the cooperation and assistance of other named defendants (who were also executives or employees of BEC). In pertinent part, the relator alleged that BEC:

  1. Engaged in fraudulent anesthesia billing by packaging cosmetic and medically necessary procedures together, but intentionally failed to deduct the cost of anesthesia for the cosmetic portion of the procedure (as legally required to do) before billing federal health care programs;
  2. Paid optometrists $100 for every patient referred to BEC’s ophthalmologists for the evaluation and treatment of cataracts in violation of the AKS;
  3. Ordered unnecessary procedures related to cataract surgery and falsified medical records to support this practice as a matter of course (specifically, scheduling nearly every patient who had undergone cataract surgery for a procedure within three months of that surgery when those patients who develop this post-cataract-surgical complication—and many do not—do not do so for one to three years after cataract surgery);
  4. Employed optometrists who exceeded their licensed scope of practice by performing surgical (or certain other) procedures that may only be performed by medical doctors; and
  5. Billed federal health care programs for Botox injections (using the CPT code for actual Botox, not the generic versions) after obtaining the Botox on the “black market” to save money or using a non-FDA-approved Botox-like substance for some of those injections.

When the relator expressed her concerns about these practices to BEC executives, they purportedly often acknowledged the issues but did nothing to remedy them. Instead, according to the relator, she experienced significant retaliation in response, including: denial of a bonus she had previously been awarded (and which BEC had already begun paying), verbal abuse, physical intimidation (including one BEC partner who raised his hand as if to strike the relator), harassing telephone calls and excessive monitoring of the relator’s computer and whereabouts. She was eventually put on probation, and she was then terminated.

Current Status: A significant portion of the docket in this case continues to be sealed, but the unsealed remainder shows that in the last month Notices of Pendency of Related Cases, Certificates of Interested Persons and Notices to Counsel have been filed. It remains to be seen whether the government will elect to intervene in, or any related cases will be joined with, this case.

Reasons to Watch: While the misconduct alleged by the relator is not necessarily unique in the context of health care fraud enforcement, this case may be one to watch because it involves several allegations regarding specific patients who were exposed to unnecessary, sometimes dangerous, procedures. Given the government’s continued (and growing) interest in prosecuting cases that involve allegations of harm to patients, it will be interesting to see whether the egregious risk of harm alleged in this case captures the government’s attention. In addition, while the retaliatory conduct alleged is on the extreme end of the spectrum, this case serves as yet another reminder that the vast majority of relators are former employees and that fair treatment and following up on employees’ complaints may go a long way toward limiting the risk of being sued by a relator under the FCA’s qui tam provisions.

United States of America and State of New York ex rel. Jamie Cantor v. Option Care, Inc., et al. No. 1:09-cv-06970 (S.D.N.Y.)

Complaint Filed: August 6, 2009

Complaint Unsealed: June 26, 2015

Intervention Status: Declination by the federal government; partial intervention by New York State.

Claims: Submission of false claims and false statements in violation of the federal (FCA, 31 U.S.C. §§ 3729 (a)(1)(A), and (a)(1)(B)); submission of false claims, false statements, and conspiracy to defraud by false claims in violation of the New York False Claims Act, New York State Finance Law §§ 187-194.

Name of Relator: Jamie Cantor

Defendant’s Business: Nursing, pharmaceutical, home care services

Relator’s Relationship to Defendant: The relator was a former sales manager for defendant Option Care, Inc. (“Option Care”).

Relator’s Counsel: Law Offices of Weiner & Weiner, LLC

Summary of Case: The relator was a former employee of Option Care and Trinity Home Care, LLC, a company that Option Care had acquired. Option Care provided nursing, pharmaceutical, and home care services to patients. The relator alleged that Option Care defrauded, and conspired with others to defraud, Medicare, Medicaid, and private insurance companies by sending patients excess medication and by providing patients with medication for which they did not sign receipts.

Current Status: The case settled in June 2015. The defendant agreed to pay $2,551,062.32 to the State of New York; the State agreed to pay the relator $459,191.22.

Reasons to Watch: This case contains a common factual scenario in qui tam actions where the relator is a former employee who had access to billing records during employment. However, the case provides an important reminder that even where federal intervention may not occur, a state government can choose to intervene, especially in states such as New York that are active in the enforcement arena.

Here, Option Care agreed to a multi-million dollar settlement with the State of New York after the State intervened (“State Settlement Agreement”) (and a few weeks later agreed to a $22.4 million settlement with the State of New York for claims involving a different drug). Even though the federal government did not intervene, the State Settlement Agreement covered both the federal and state shares of the Medicaid reimbursements, providing that “the State shall tender to the United States a percentage of the Settlement Amount as agreed by the State and the United States in accord with the Federal Medicaid Assistance percentage rate.” The State Settlement Agreement also made clear that neither the State nor the relator could release any claims brought on behalf of the United States. Separately, the relator—not including any defendants—entered into a stipulation and release with the United States. The federal release recognizes that the relator received a share of the proceeds of the State Settlement Agreement, and the relator stipulated that the settlement of the State claims was a fair settlement. Under the federal stipulation and release, the relator agreed to release the United States from (1) any claims for a share of the state settlement, including claims under the federal FCA; and (2) any claims arising from or relating to the relator’s lawsuit against any of the defendants.

Although the defendant resolved the State claims, as discussed by our colleague Ellyn Sternfield, state settlements without federal government intervention pose a risk for defendants. Even though the federal government did not object to the State Settlement Agreement in this case, the United States did not provide the defendants with a federal release. In addition, HHS-OIG was not a party to the settlement, so the defendants did not obtain a release from OIG’s exclusion authority. As a result, the defendants remain subject to potential additional liability.

[View source.]

Written by:

Mintz - Health Care Viewpoints

Mintz - Health Care Viewpoints on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at:

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit
  • New Relic - For more information on New Relic cookies, please visit
  • Google Analytics - For more information on Google Analytics cookies, visit To opt-out of being tracked by Google Analytics across all websites visit This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at:

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.